Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Nashville, Tennessee 37023


Purpose:

Additional active agents are needed to further improve the treatment of patients with CLL/SLL. Increasing information exists regarding the activity of arsenic trioxide in other hematologic malignancies. Since arsenic trioxide produces mild to moderate myelosuppression and is not as immunosuppressive as other available agents, it may be an additional treatment option for CLL/SLL. This study will evaluate the feasibility and toxicity of arsenic trioxide in patients with relapsed or refractory CLL/SLL


Study summary:

Upon determination of eligibility, patients will receive: - Arsenic Trioxide


Criteria:

Inclusion Criteria: To be included in this study, you must meet the following criteria: - Histologically proven B-cell CLL/SLL. - Must have had a minimum of 1 and a maximum of 3 previous systemic regimens - Must have progressive CLL/SLL - Measurable or evaluable disease - ECOG performance status 0, 1, or 2 - Age > 18 years. - Patients with cytopenias caused by bone marrow involvement are eligible - All patients must give written informed consent prior to entering this study. Exclusion Criteria: You cannot participate in this study if any of the following apply to you: - Unstable active infection on the basis of neutropenia - Previous severe opportunistic infections - Severe immune mediated anemia or thrombocytopenia - Serious underlying medical conditions - Brain metastases or meningeal involvement - History of other neoplasms - Significant underlying heart dysfunction - Women who are pregnant or Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.


NCT ID:

NCT00193518


Primary Contact:

Principal Investigator
John D. Hainsworth, MD
Sarah Cannon Research Institute


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37023
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.